USA - engelsk - NLM (National Library of Medicine)

par pharmaceutical - prednisolone (unii: 9phq9y1olm) (prednisolone - unii:9phq9y1olm) - prednisolone 15 mg in 5 ml - prednisolone syrup (prednisolone oral solution usp) is indicated in the following conditions: 1. endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2. rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis 3. collagen diseases during an exacerbation or as maintenance therapy in selected cases of: sy

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

hikma farmaceutica (portugal) sa - méthylprednisolone 500 mg sous forme de : méthylprednisolone sodique (succinate de) 663 mg - poudre - 500 mg - pour un flacon > méthylprednisolone 500 mg sous forme de : méthylprednisolone sodique (succinate de 663 mg - corticostéroïde à usage systémique - classe pharmacothérapeutique : corticostéroïde à usage systémique - code atc : h02ab04la méthylprednisolone est la substance active pour la méthylprednisolone, poudre pour solution injectable.methylprednisolone hikma contient du succinate de méthylprednisolone sodique.methylprednisolone hikma appartient à un groupe de médicaments appelés corticostéroïdes (stéroïdes).les corticostéroïdes sont produits naturellement dans votre corps et sont très important pour beaucoup des fonctions de votre organisme.booster votre organisme avec des corticostéroïdes externes tels que methylprednisolone hikma peut aider pour les opérations à venir (ex : greffe d’organes), pour les poussées de sclérose en plaques ou les autres conditions de stress.la méthylprednisolone peut être utilisée pour traiter les maladies suivantes :conditions allergiques :asthme bronchique.Œdème aigu de la gorge d’origine non infectieuse.rhinite allergique pérenne sévère.gonflement de la bouche, la langue et la trachée, qui peut causer des difficultés pour respirer (œdème de quincke)réaction allergique très sévère (anaphylaxie)troubles de la peaumaladie inflammatoire sévère de la peau.phases critiques des maladies gastro-intestinalesinflammation du gros intestin et de l’intestin grêle (maladie de crohn).troubles neurologiques :dans certains cas d’œdèmes cérébraux, atteinte sévère de la corde spinale ou poussées de sclérose en plaques.maladies respiratoiresaspiration du contenu gastrique.maladie inflammatoire sévère affectant les poumons.autres maladiesdans certains cas de méningites causées par des pathogènes responsables de tuberculose.pour réduire les réactions du système immun en cas de transplantation d’organe.contactez votre médecin si vous ne vous sentez pas mieux ou que vous vous sentez mal.

USA - engelsk - NLM (National Library of Medicine)

mission pharmacal company - prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - prednisolone 25 mg in 5 ml - prednisolone sodium phosphate oral solution (25 mg prednisolone per 5 ml) is indicated in the following conditions: 1. allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. dermatologic diseases pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (stevens-johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. edematous states to induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephritic syndrome, without uremia. 4. endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; i

USA - engelsk - NLM (National Library of Medicine)

prasco laboratories - prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - prednisolone 10 mg - prednisolone sodium phosphate orally disintegrating tablets are indicated in the treatment of the following diseases or conditions: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: - atopic dermatitis - drug hypersensitivity reactions - seasonal or perennial allergic rhinitis - serum sickness - bullous dermatitis herpetiformis - contact dermatitis - exfoliative erythroderma - mycosis fungoides - pemphigus - severe erythema multiforme (stevens-johnson syndrome) - congenital adrenal hyperplasia - hypercalcemia of malignancy - nonsuppurative thyroiditis - primary or secondary adrenocortical insufficiency: hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable. during acute episodes in: - crohn's disease - ulcerative colitis - acquired (autoimmune) hemolytic anemia - diamond-blackfan anemia - idiopathic thrombocytopenic purpura in

USA - engelsk - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - methylprednisolone (unii: x4w7zr7023) (methylprednisolone - unii:x4w7zr7023) - methylprednisolone 4 mg - methylprednisolone tablets are indicated in the following conditions: systemic fungal infections and known hypersensitivity to components.

USA - engelsk - NLM (National Library of Medicine)

bryant ranch prepack - methylprednisolone (unii: x4w7zr7023) (methylprednisolone - unii:x4w7zr7023) - methylprednisolone 4 mg - methylprednisolone tablets are indicated in the following conditions: 1.endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2.rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis synovitis of osteoarthritis acute nonspecific tenosynovitis post-traumatic osteoarthritis psoriatic arthritis epicondylitis acute gouty arthritis 3.collagen diseases during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus s

USA - engelsk - NLM (National Library of Medicine)

pharmaceutical associates, inc. - prednisolone (unii: 9phq9y1olm) (prednisolone - unii:9phq9y1olm) - solution - 15 mg in 5 ml - prednisolone syrup (prednisolone oral solution usp) is indicated in the following conditions: - endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable: in infancy mineralocorticoid supplementation is of particular importance).    congenital adrenal hyperplasia    nonsuppurative thyroiditis    hypercalcemia associated with cancer - rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:    psoriatic arthritis    rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)    ankylosing spondylitis    acute and subacute bursitis    acute nonspecific tenosynovitis    acute gouty arthritis    post-traumatic osteoarthritis    synovitis of osteoarthritis    epicondylitis - collagen diseases during an exacer

USA - engelsk - NLM (National Library of Medicine)

preferred pharmaceuticals inc - prednisolone (unii: 9phq9y1olm) (prednisolone - unii:9phq9y1olm) - prednisolone syrup (prednisolone oral solution usp) is indicated in the following conditions: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus acute rheumatic carditis pemphigus bullo

USA - engelsk - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - prednisolone (unii: 9phq9y1olm) (prednisolone - unii:9phq9y1olm) - prednisolone 15 mg in 5 ml - prednisolone oral solution is indicated in the following conditions: 1. endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2. rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis 3. collagen diseases during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematos

USA - engelsk - NLM (National Library of Medicine)

apotheca inc. - prednisolone (unii: 9phq9y1olm) (prednisolone - unii:9phq9y1olm) - prednisolone 15 mg in 5 ml - prednisolone oral solution is indicated in the following conditions: 1. endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2. rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis 3. collagen diseases during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematos